Cassava Sciences Review by Journal of Neuroscience Shows no Evidence of Data Manipulation
Nov 4, 2021 By MarketDepth
Cassava Sciences, Inc. (NASDAQ: SAVA) has been notified by the Journal of Neuroscience that there is no supporting evidence of data manipulation in an article published in July 2012 that describes a new approach to treating Alzheimer’s disease. The reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences, which holds the foundation to simufilam, the Company’s lead drug candidate for the proposed treatment of Alzheimer’s disease. “I’ve never doubted the integrity of our people or science,” said Remi Barbier, President & CEO. “We remain focused on conducting a Phase 3 clinical program of simufilam in people with Alzheimer’s disease. It’s an important endeavor, notwithstanding pundits who may be louder than they are learned. We’ll stay the course until our job is done.”
The Journal of Neuroscience authorized Cassava Sciences to share a statement on this matter, reprinted in full below:
“The Journal of Neuroscience follows COPE [Committee on Publication Ethics] guidelines and takes any claims of misconduct very seriously. In response to allegations of data manipulation in JNeurosci 2012;32:9773-9784 the Journal requested raw data, including images of original, uncropped Western blots. The Journal determined that there was one duplicated panel in Figure 8 and a Corrigendum was requested and will be printed. No evidence of data manipulation was found for Western blot data.”
